{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-25-000092","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.655747+00:00","generated_at":"2026-05-17T23:33:57.884998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook","bullets":["Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).","Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.","Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.","Completed enrollment of 6,500 patients in the LeAAPS trial.","Company raised full-year 2025 financial outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-25-000092","json":"https://secwatch.observer/filing/0001323885-25-000092.json","markdown":"https://secwatch.observer/filing/0001323885-25-000092.md","text":"https://secwatch.observer/filing/0001323885-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/0001323885-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/atrc-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:33:57.884998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}